Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nal-IRI for progressing brain metastases in HER2-negative breast cancer
2016-002689-30Phase 2Active
- Sponsor
- MEDSIR
- Start
- Jan 2017
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan in breast cancer, sponsored by MEDSIR. Primary endpoint: Central Nervous System Overall Response Rate. Started Jan 2017; status: active.
02
Drugs
nanoliposomal irinotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-002689-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002689-30.